<DOC>
	<DOCNO>NCT02550964</DOCNO>
	<brief_summary>The purpose study evaluate incidence risk factor toxic maculopathy treat hydroxychloroquine chloroquine due autoimmune disease rheumatoid arthritis systemic lupus erythematosus . Total 5-year study period , investigator screen patient baseline examination ( Fundus photography , fundus autofluorescence , spectral-domain optical coherence tomography , Humphrey visual field test multifocal electroretinography ) observe examination every year .</brief_summary>
	<brief_title>Incidence Risk Factor Hydroxychloroquine Chloroquine Retinopathy</brief_title>
	<detailed_description />
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Patient treat HCQ CQ due autoimmune disease RA , SLE Patient previously diagnose HCQ/CQ toxic retinopathy Aged le 19 year</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Autoimmune Disease</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Hydroxychloroquine ( HCQ )</keyword>
	<keyword>Chloroquine ( CQ )</keyword>
	<keyword>Toxic Maculopathy</keyword>
</DOC>